| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Plasmids | 16 | 2023 | 258 | 5.040 |
Why?
|
| Escherichia coli | 9 | 2023 | 368 | 3.200 |
Why?
|
| Pancreatitis, Chronic | 6 | 2020 | 168 | 2.250 |
Why?
|
| Drug Resistance, Bacterial | 5 | 2018 | 98 | 2.230 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 5 | 2021 | 47 | 1.860 |
Why?
|
| Acinetobacter baumannii | 4 | 2022 | 22 | 1.850 |
Why?
|
| Anti-Bacterial Agents | 14 | 2022 | 1026 | 1.710 |
Why?
|
| Escherichia coli Proteins | 3 | 2018 | 65 | 1.700 |
Why?
|
| Pancreatitis | 8 | 2019 | 279 | 1.580 |
Why?
|
| Pancreatitis, Acute Necrotizing | 3 | 2021 | 11 | 1.530 |
Why?
|
| DNA, Bacterial | 3 | 2019 | 150 | 1.320 |
Why?
|
| DNA Transposable Elements | 5 | 2020 | 20 | 1.300 |
Why?
|
| Bacterial Infections | 2 | 2021 | 163 | 1.200 |
Why?
|
| Genome, Bacterial | 4 | 2023 | 20 | 1.150 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2018 | 120 | 1.140 |
Why?
|
| Myotomy | 3 | 2021 | 14 | 1.090 |
Why?
|
| Integrons | 4 | 2020 | 4 | 1.050 |
Why?
|
| beta-Lactamases | 8 | 2022 | 33 | 1.010 |
Why?
|
| Genes, Bacterial | 4 | 2021 | 40 | 0.970 |
Why?
|
| Carrier Proteins | 3 | 2017 | 597 | 0.970 |
Why?
|
| Pain | 2 | 2018 | 472 | 0.950 |
Why?
|
| Pancreatic Neoplasms | 5 | 2020 | 332 | 0.890 |
Why?
|
| Gastric Bypass | 2 | 2021 | 83 | 0.850 |
Why?
|
| Gram-Negative Bacteria | 2 | 2020 | 55 | 0.830 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 5 | 2021 | 348 | 0.820 |
Why?
|
| Base Sequence | 7 | 2019 | 1015 | 0.790 |
Why?
|
| Pancreatectomy | 3 | 2017 | 129 | 0.780 |
Why?
|
| Symbiosis | 2 | 2018 | 19 | 0.730 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2020 | 24 | 0.730 |
Why?
|
| Esophageal Achalasia | 1 | 2020 | 78 | 0.710 |
Why?
|
| Trypsin | 2 | 2017 | 64 | 0.670 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 2017 | 101 | 0.670 |
Why?
|
| Mosaicism | 1 | 2019 | 21 | 0.660 |
Why?
|
| Conjugation, Genetic | 1 | 2018 | 7 | 0.660 |
Why?
|
| Virulence | 2 | 2020 | 51 | 0.640 |
Why?
|
| Gastric Fistula | 1 | 2018 | 6 | 0.640 |
Why?
|
| Cutaneous Fistula | 1 | 2018 | 11 | 0.640 |
Why?
|
| Mutation | 4 | 2018 | 1213 | 0.590 |
Why?
|
| Humans | 55 | 2022 | 68618 | 0.580 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 475 | 0.560 |
Why?
|
| Ileus | 1 | 2016 | 7 | 0.560 |
Why?
|
| Pain Management | 1 | 2018 | 186 | 0.560 |
Why?
|
| Endoscopy, Gastrointestinal | 4 | 2018 | 171 | 0.550 |
Why?
|
| Retrospective Studies | 18 | 2022 | 7277 | 0.550 |
Why?
|
| Dihydropteroate Synthase | 1 | 2016 | 1 | 0.540 |
Why?
|
| Analgesics, Opioid | 3 | 2019 | 498 | 0.540 |
Why?
|
| Endosonography | 5 | 2021 | 177 | 0.530 |
Why?
|
| Penetrance | 1 | 2016 | 17 | 0.530 |
Why?
|
| Pain, Postoperative | 2 | 2017 | 214 | 0.530 |
Why?
|
| Nociceptive Pain | 1 | 2015 | 1 | 0.520 |
Why?
|
| Transient Receptor Potential Channels | 1 | 2015 | 5 | 0.520 |
Why?
|
| TRPV Cation Channels | 1 | 2015 | 17 | 0.520 |
Why?
|
| Calcinosis | 2 | 2018 | 241 | 0.520 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2016 | 51 | 0.520 |
Why?
|
| Calcium Channels | 1 | 2015 | 59 | 0.510 |
Why?
|
| Stents | 4 | 2021 | 657 | 0.490 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 170 | 0.480 |
Why?
|
| Analgesics | 1 | 2015 | 118 | 0.470 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 4 | 2018 | 10 | 0.470 |
Why?
|
| Gene Expression | 1 | 2016 | 770 | 0.460 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 290 | 0.450 |
Why?
|
| Klebsiella pneumoniae | 3 | 2022 | 18 | 0.450 |
Why?
|
| Streptomycin | 3 | 2018 | 12 | 0.440 |
Why?
|
| Adult | 22 | 2021 | 21403 | 0.430 |
Why?
|
| DNA Replication | 3 | 2019 | 167 | 0.430 |
Why?
|
| Endoscopy, Digestive System | 4 | 2021 | 78 | 0.410 |
Why?
|
| Klebsiella Infections | 2 | 2022 | 13 | 0.390 |
Why?
|
| Drainage | 3 | 2021 | 133 | 0.380 |
Why?
|
| Bacterial Proteins | 3 | 2022 | 245 | 0.360 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2021 | 226 | 0.360 |
Why?
|
| Middle Aged | 20 | 2021 | 21147 | 0.360 |
Why?
|
| Zenker Diverticulum | 2 | 2021 | 7 | 0.350 |
Why?
|
| Lithotripsy | 2 | 2020 | 18 | 0.340 |
Why?
|
| Female | 27 | 2021 | 38074 | 0.340 |
Why?
|
| Male | 25 | 2021 | 37321 | 0.330 |
Why?
|
| Abdominal Pain | 3 | 2019 | 97 | 0.320 |
Why?
|
| Tetracycline Resistance | 2 | 2020 | 3 | 0.320 |
Why?
|
| Treatment Outcome | 8 | 2021 | 7029 | 0.320 |
Why?
|
| Cohort Studies | 3 | 2020 | 2358 | 0.310 |
Why?
|
| Suture Techniques | 2 | 2018 | 75 | 0.310 |
Why?
|
| Pancreas | 3 | 2018 | 225 | 0.300 |
Why?
|
| Gastrostomy | 2 | 2018 | 110 | 0.290 |
Why?
|
| Proteins | 5 | 2009 | 474 | 0.290 |
Why?
|
| Spectinomycin | 2 | 2017 | 2 | 0.280 |
Why?
|
| Osteoblasts | 5 | 2009 | 99 | 0.280 |
Why?
|
| Replicon | 2 | 2017 | 13 | 0.280 |
Why?
|
| Australia | 2 | 2017 | 235 | 0.260 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 786 | 0.250 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 208 | 0.240 |
Why?
|
| Acute Disease | 3 | 2021 | 658 | 0.240 |
Why?
|
| Metals | 3 | 2020 | 100 | 0.240 |
Why?
|
| Basal Metabolism | 2 | 2014 | 22 | 0.240 |
Why?
|
| Drug Resistance, Microbial | 2 | 2022 | 70 | 0.230 |
Why?
|
| Multilocus Sequence Typing | 3 | 2021 | 7 | 0.230 |
Why?
|
| Aged | 11 | 2021 | 14862 | 0.220 |
Why?
|
| Phenotype | 2 | 2017 | 947 | 0.220 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2017 | 2324 | 0.220 |
Why?
|
| Physical Fitness | 2 | 2014 | 117 | 0.220 |
Why?
|
| Osteogenesis | 3 | 2009 | 152 | 0.210 |
Why?
|
| Phylogeny | 3 | 2022 | 197 | 0.210 |
Why?
|
| Alcaligenes faecalis | 1 | 2021 | 1 | 0.200 |
Why?
|
| Constriction, Pathologic | 2 | 2020 | 236 | 0.200 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2021 | 2 | 0.190 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2021 | 85 | 0.190 |
Why?
|
| Proteus mirabilis | 1 | 2020 | 1 | 0.190 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 7 | 0.190 |
Why?
|
| Pseudomonas Infections | 1 | 2021 | 83 | 0.190 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2020 | 22 | 0.190 |
Why?
|
| Breast Neoplasms | 2 | 2021 | 1536 | 0.190 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2020 | 68 | 0.180 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 4848 | 0.180 |
Why?
|
| Calculi | 1 | 2020 | 7 | 0.180 |
Why?
|
| Risk Factors | 3 | 2021 | 5731 | 0.180 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 67 | 0.180 |
Why?
|
| Gastroenterologists | 1 | 2020 | 11 | 0.180 |
Why?
|
| Hydrogen Peroxide | 1 | 2021 | 168 | 0.180 |
Why?
|
| Multimodal Imaging | 1 | 2020 | 62 | 0.180 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2020 | 46 | 0.180 |
Why?
|
| Electric Impedance | 1 | 2020 | 131 | 0.180 |
Why?
|
| Bile Ducts | 1 | 2020 | 59 | 0.170 |
Why?
|
| Heterozygote | 2 | 2018 | 174 | 0.170 |
Why?
|
| Conserved Sequence | 1 | 2019 | 67 | 0.170 |
Why?
|
| Kanamycin Resistance | 1 | 2019 | 2 | 0.170 |
Why?
|
| Restriction Mapping | 1 | 2019 | 85 | 0.170 |
Why?
|
| Sulfamethoxazole | 1 | 2018 | 15 | 0.160 |
Why?
|
| Ampicillin | 1 | 2018 | 17 | 0.160 |
Why?
|
| Base Pairing | 1 | 2018 | 15 | 0.160 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 96 | 0.160 |
Why?
|
| Wnt Proteins | 3 | 2009 | 57 | 0.160 |
Why?
|
| Recurrence | 2 | 2018 | 948 | 0.160 |
Why?
|
| Argon Plasma Coagulation | 1 | 2018 | 2 | 0.160 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2018 | 15 | 0.160 |
Why?
|
| Chromosome Mapping | 1 | 2019 | 188 | 0.160 |
Why?
|
| Common Bile Duct | 1 | 2018 | 22 | 0.160 |
Why?
|
| Intubation, Gastrointestinal | 2 | 2018 | 48 | 0.160 |
Why?
|
| Esophageal Sphincter, Upper | 1 | 2018 | 7 | 0.160 |
Why?
|
| Sequence Alignment | 1 | 2018 | 165 | 0.160 |
Why?
|
| Anal Canal | 1 | 2018 | 28 | 0.150 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2018 | 20 | 0.150 |
Why?
|
| Cholecystectomy | 1 | 2018 | 79 | 0.150 |
Why?
|
| Jejunostomy | 1 | 2018 | 26 | 0.150 |
Why?
|
| Anastomotic Leak | 1 | 2018 | 11 | 0.150 |
Why?
|
| Self Expandable Metallic Stents | 1 | 2018 | 14 | 0.150 |
Why?
|
| Gastrectomy | 1 | 2018 | 24 | 0.150 |
Why?
|
| Cholestasis | 1 | 2018 | 90 | 0.150 |
Why?
|
| Sulfonamides | 2 | 2009 | 141 | 0.150 |
Why?
|
| Pain Measurement | 2 | 2017 | 328 | 0.150 |
Why?
|
| Pancreatic Diseases | 1 | 2018 | 66 | 0.150 |
Why?
|
| Gastroenterostomy | 1 | 2017 | 8 | 0.150 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2017 | 5 | 0.150 |
Why?
|
| Furosemide | 1 | 2017 | 45 | 0.150 |
Why?
|
| Delayed Graft Function | 1 | 2017 | 39 | 0.150 |
Why?
|
| Multiple Organ Failure | 1 | 2017 | 36 | 0.150 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2017 | 34 | 0.150 |
Why?
|
| Chymotrypsin | 1 | 2017 | 11 | 0.150 |
Why?
|
| Trimethoprim Resistance | 1 | 2017 | 4 | 0.150 |
Why?
|
| Colon | 1 | 2018 | 168 | 0.140 |
Why?
|
| Enteral Nutrition | 2 | 2018 | 157 | 0.140 |
Why?
|
| Gastroparesis | 1 | 2017 | 7 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 492 | 0.140 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2017 | 52 | 0.140 |
Why?
|
| Escherichia coli Infections | 1 | 2017 | 47 | 0.140 |
Why?
|
| Open Reading Frames | 1 | 2016 | 25 | 0.140 |
Why?
|
| Device Removal | 1 | 2018 | 100 | 0.140 |
Why?
|
| Gene Order | 1 | 2016 | 13 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2020 | 326 | 0.140 |
Why?
|
| Body Composition | 2 | 2014 | 119 | 0.140 |
Why?
|
| Genomic Instability | 1 | 2016 | 41 | 0.140 |
Why?
|
| Pancreatic Cyst | 1 | 2016 | 16 | 0.140 |
Why?
|
| Body Mass Index | 3 | 2015 | 867 | 0.140 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2016 | 8 | 0.140 |
Why?
|
| Lymphoma, T-Cell | 1 | 2016 | 19 | 0.140 |
Why?
|
| Chloramphenicol | 1 | 2016 | 7 | 0.140 |
Why?
|
| Trimethoprim | 1 | 2016 | 8 | 0.140 |
Why?
|
| Chylous Ascites | 1 | 2016 | 11 | 0.140 |
Why?
|
| beta-Lactam Resistance | 1 | 2016 | 6 | 0.140 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2016 | 20 | 0.130 |
Why?
|
| Heredity | 1 | 2016 | 9 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 1465 | 0.130 |
Why?
|
| Nose Neoplasms | 1 | 2016 | 25 | 0.130 |
Why?
|
| Tissue Donors | 1 | 2017 | 195 | 0.130 |
Why?
|
| TRPA1 Cation Channel | 1 | 2015 | 2 | 0.130 |
Why?
|
| Duodenal Diseases | 1 | 2015 | 15 | 0.130 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 438 | 0.130 |
Why?
|
| Pedigree | 1 | 2016 | 159 | 0.130 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 159 | 0.130 |
Why?
|
| Pancreatic Fistula | 1 | 2015 | 23 | 0.130 |
Why?
|
| Obesity, Morbid | 1 | 2018 | 172 | 0.130 |
Why?
|
| Computational Biology | 1 | 2017 | 190 | 0.130 |
Why?
|
| Molecular Typing | 1 | 2015 | 5 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 536 | 0.130 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 78 | 0.120 |
Why?
|
| Risk | 1 | 2016 | 563 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2016 | 714 | 0.120 |
Why?
|
| Hospital Mortality | 1 | 2016 | 384 | 0.120 |
Why?
|
| Recombination, Genetic | 1 | 2014 | 62 | 0.120 |
Why?
|
| Deglutition Disorders | 1 | 2018 | 297 | 0.120 |
Why?
|
| Motor Activity | 2 | 2015 | 621 | 0.120 |
Why?
|
| Receptors, Cell Surface | 2 | 2006 | 248 | 0.120 |
Why?
|
| Weight Gain | 1 | 2015 | 135 | 0.120 |
Why?
|
| Carcinoma, Papillary | 1 | 2014 | 35 | 0.120 |
Why?
|
| Young Adult | 4 | 2018 | 5717 | 0.120 |
Why?
|
| Hospitalization | 1 | 2019 | 978 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2014 | 221 | 0.110 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 1447 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 508 | 0.100 |
Why?
|
| Exercise | 2 | 2015 | 658 | 0.100 |
Why?
|
| Disease Progression | 1 | 2015 | 1038 | 0.100 |
Why?
|
| Body Weight | 1 | 2014 | 554 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 2223 | 0.100 |
Why?
|
| Homologous Recombination | 2 | 2021 | 13 | 0.090 |
Why?
|
| Genomics | 2 | 2023 | 168 | 0.090 |
Why?
|
| Quality of Life | 2 | 2017 | 1515 | 0.090 |
Why?
|
| Osteocytes | 2 | 2009 | 8 | 0.090 |
Why?
|
| Kidney Transplantation | 1 | 2017 | 839 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 5 | 2009 | 216 | 0.090 |
Why?
|
| Pregnancy | 1 | 2015 | 2334 | 0.080 |
Why?
|
| Sulfones | 1 | 2008 | 45 | 0.080 |
Why?
|
| Logistic Models | 3 | 2017 | 1420 | 0.080 |
Why?
|
| South Carolina | 3 | 2021 | 2752 | 0.080 |
Why?
|
| Ultrasonography, Interventional | 2 | 2018 | 119 | 0.070 |
Why?
|
| Fatal Outcome | 2 | 2018 | 164 | 0.070 |
Why?
|
| Bone Density | 2 | 2008 | 159 | 0.070 |
Why?
|
| ROC Curve | 2 | 2017 | 392 | 0.070 |
Why?
|
| Pluripotent Stem Cells | 1 | 2006 | 42 | 0.070 |
Why?
|
| Necrosis | 2 | 2018 | 239 | 0.070 |
Why?
|
| Mice | 7 | 2022 | 8474 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1140 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 146 | 0.060 |
Why?
|
| Receptors, LDL | 1 | 2003 | 72 | 0.050 |
Why?
|
| Drug Resistance, Multiple | 1 | 2023 | 56 | 0.050 |
Why?
|
| Apoptosis | 2 | 2009 | 1641 | 0.050 |
Why?
|
| Inosine Monophosphate | 1 | 2022 | 1 | 0.050 |
Why?
|
| Serogroup | 1 | 2022 | 6 | 0.050 |
Why?
|
| Carbapenems | 1 | 2022 | 7 | 0.050 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2022 | 32 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2008 | 2689 | 0.050 |
Why?
|
| beta-Lactams | 1 | 2021 | 29 | 0.050 |
Why?
|
| Esophagoscopy | 1 | 2021 | 72 | 0.050 |
Why?
|
| Fosfomycin | 1 | 2020 | 4 | 0.050 |
Why?
|
| Genome Size | 1 | 2020 | 4 | 0.050 |
Why?
|
| Amikacin | 1 | 2020 | 13 | 0.050 |
Why?
|
| Genetic Fitness | 1 | 2020 | 8 | 0.050 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2021 | 40 | 0.050 |
Why?
|
| Clone Cells | 1 | 2021 | 67 | 0.050 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2021 | 133 | 0.050 |
Why?
|
| Tetracycline | 1 | 2020 | 29 | 0.050 |
Why?
|
| Urologists | 1 | 2020 | 7 | 0.050 |
Why?
|
| Animals | 7 | 2022 | 20881 | 0.050 |
Why?
|
| Sputum | 1 | 2020 | 51 | 0.050 |
Why?
|
| China | 1 | 2021 | 138 | 0.050 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 79 | 0.040 |
Why?
|
| United States | 3 | 2021 | 7367 | 0.040 |
Why?
|
| Hematocrit | 1 | 2019 | 70 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 2279 | 0.040 |
Why?
|
| Cell Differentiation | 3 | 2009 | 1034 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2009 | 2673 | 0.040 |
Why?
|
| Laryngopharyngeal Reflux | 1 | 2018 | 5 | 0.040 |
Why?
|
| Medical Records | 1 | 2019 | 121 | 0.040 |
Why?
|
| Calcification, Physiologic | 2 | 2009 | 31 | 0.040 |
Why?
|
| Plastics | 1 | 2018 | 25 | 0.040 |
Why?
|
| Surgical Stapling | 1 | 2018 | 3 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2018 | 104 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 792 | 0.040 |
Why?
|
| Skull | 2 | 2009 | 63 | 0.040 |
Why?
|
| Equipment Failure | 1 | 2018 | 112 | 0.040 |
Why?
|
| Organ Culture Techniques | 2 | 2009 | 122 | 0.040 |
Why?
|
| Inpatients | 1 | 2019 | 208 | 0.040 |
Why?
|
| Diuretics | 1 | 2017 | 97 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 955 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 306 | 0.040 |
Why?
|
| Gastrointestinal Motility | 1 | 2017 | 52 | 0.040 |
Why?
|
| Registries | 1 | 2020 | 733 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 145 | 0.030 |
Why?
|
| Cystadenoma | 1 | 2016 | 10 | 0.030 |
Why?
|
| Paracentesis | 1 | 2016 | 25 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2022 | 2455 | 0.030 |
Why?
|
| Reoperation | 1 | 2018 | 467 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2017 | 220 | 0.030 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 2 | 2006 | 2 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 504 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 652 | 0.030 |
Why?
|
| Calcium Chelating Agents | 1 | 2015 | 5 | 0.030 |
Why?
|
| Intestinal Fistula | 1 | 2015 | 26 | 0.030 |
Why?
|
| Protease Inhibitors | 1 | 2015 | 76 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 2015 | 59 | 0.030 |
Why?
|
| Podocytes | 1 | 2016 | 113 | 0.030 |
Why?
|
| Self Report | 1 | 2017 | 371 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1046 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 201 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 2550 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 3259 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2015 | 115 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 540 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2015 | 291 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 3705 | 0.030 |
Why?
|
| Energy Intake | 1 | 2014 | 123 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 349 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 285 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2014 | 258 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 880 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 2093 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2014 | 222 | 0.030 |
Why?
|
| Linear Models | 1 | 2014 | 521 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1851 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 1753 | 0.030 |
Why?
|
| Diet | 1 | 2015 | 514 | 0.020 |
Why?
|
| Cell Line | 2 | 2006 | 1752 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2005 | 1664 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 1593 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 4655 | 0.020 |
Why?
|
| Frizzled Receptors | 1 | 2009 | 8 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2005 | 1293 | 0.020 |
Why?
|
| RANK Ligand | 1 | 2009 | 73 | 0.020 |
Why?
|
| Biochemistry | 1 | 2008 | 12 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2009 | 112 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 2800 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2009 | 397 | 0.020 |
Why?
|
| Drug Design | 1 | 2008 | 107 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2008 | 420 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2008 | 155 | 0.020 |
Why?
|
| Sp7 Transcription Factor | 1 | 2006 | 4 | 0.020 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2006 | 6 | 0.020 |
Why?
|
| Osteocalcin | 1 | 2006 | 37 | 0.020 |
Why?
|
| Obesity | 1 | 2014 | 1076 | 0.020 |
Why?
|
| Rats | 2 | 2005 | 5300 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2006 | 100 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2006 | 95 | 0.020 |
Why?
|
| Annexin A5 | 1 | 2005 | 16 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2006 | 150 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2005 | 201 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2006 | 447 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2005 | 126 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2005 | 110 | 0.020 |
Why?
|
| Wnt3 Protein | 1 | 2004 | 3 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2006 | 222 | 0.020 |
Why?
|
| Wnt1 Protein | 1 | 2004 | 9 | 0.020 |
Why?
|
| beta Catenin | 1 | 2004 | 73 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2005 | 376 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 710 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 1851 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2004 | 108 | 0.010 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-5 | 1 | 2003 | 2 | 0.010 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2003 | 4 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 2003 | 71 | 0.010 |
Why?
|
| Bone Development | 1 | 2003 | 37 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2004 | 237 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2005 | 384 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2004 | 238 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2003 | 204 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 302 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2003 | 145 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2004 | 615 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2006 | 753 | 0.010 |
Why?
|
| Osteoclasts | 1 | 2003 | 132 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 1027 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2004 | 1200 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 8912 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 1033 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2004 | 1692 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2003 | 689 | 0.010 |
Why?
|
| Aging | 1 | 2003 | 911 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2003 | 2791 | 0.010 |
Why?
|